Literature DB >> 23226655

Metformin: Midlife maturity, maiden charm.

Sanjay Kalra1, Puneet Dhamija, Ashok K Das.   

Abstract

Metformin is one of the most commonly prescribed drugs for management of Type 2 diabetes mellitus. It has been in use for almost five decades. Now, pharmacological properties of this agent are being exapted for use in a number of other indications. New facets of its personality are coming up, generating more interest of the scientific community in this "middle-aged" molecule. This article explores the role of metformin in cardioprotection and its hepatoprotective properties. Nephroprotective, protection against excess body fat and gonadoprotective actions, properties have also been discussed. Additionally, this manuscript briefly reviews the thyroid stimulating hormone (TSH)-lowering properties in diabetic and non-diabetic patients, besides reviewing its actions on different types of cancers. Some of these actions may become approved indications for use of metformin following generation of new evidence. Metformin still has many unexplored dimensions that deserve further exploration.

Entities:  

Keywords:  Biguanides; cancer; cardioprotection; diabetes; gonad; hepatoprotection; oral hypoglycemic drugs; renoprotection; thyroid

Year:  2012        PMID: 23226655      PMCID: PMC3510929          DOI: 10.4103/2230-8210.103028

Source DB:  PubMed          Journal:  Indian J Endocrinol Metab        ISSN: 2230-9500


  47 in total

1.  Thyreotropin levels in diabetic patients on metformin treatment.

Authors:  Carlo Cappelli; Mario Rotondi; Ilenia Pirola; Barbara Agosti; Annamaria Formenti; Emanuela Zarra; Umberto Valentini; Paola Leporati; Luca Chiovato; Maurizio Castellano
Journal:  Eur J Endocrinol       Date:  2012-05-29       Impact factor: 6.664

2.  [Effects of metformin on proliferation of human colon carcinoma cell line SW-480].

Authors:  Xiao-zhi Zhou; Yao-ming Xue; Bo Zhu; Jian-ping Sha
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2010-08

3.  Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer.

Authors:  Soley Bayraktar; Leonel F Hernadez-Aya; Xiudong Lei; Funda Meric-Bernstam; Jennifer K Litton; Limin Hsu; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo
Journal:  Cancer       Date:  2011-07-28       Impact factor: 6.860

4.  Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program.

Authors: 
Journal:  Diabetes Care       Date:  2003-04       Impact factor: 19.112

5.  Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells.

Authors:  Vlad C Sandulache; Thomas J Ow; Curtis R Pickering; Mitchell J Frederick; Ge Zhou; Izabela Fokt; Melinda Davis-Malesevich; Waldemar Priebe; Jeffrey N Myers
Journal:  Cancer       Date:  2011-01-10       Impact factor: 6.860

6.  Investigation of the potential effects of metformin on atherothrombotic risk factors in hyperlipidemic rats.

Authors:  Somsuvra B Ghatak; Prakash S Dhamecha; Shraddha V Bhadada; Shital J Panchal
Journal:  Eur J Pharmacol       Date:  2011-04-02       Impact factor: 4.432

Review 7.  The cardioprotective effects of metformin.

Authors:  Saloua El Messaoudi; Gerard A Rongen; Rudolf A de Boer; Niels P Riksen
Journal:  Curr Opin Lipidol       Date:  2011-12       Impact factor: 4.776

8.  Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells.

Authors:  A Vazquez-Martin; C Oliveras-Ferraros; S Cufí; B Martin-Castillo; J A Menendez
Journal:  Curr Mol Med       Date:  2010-10       Impact factor: 2.222

9.  Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth.

Authors:  Krisztina Kisfalvi; Guido Eibl; James Sinnett-Smith; Enrique Rozengurt
Journal:  Cancer Res       Date:  2009-08-15       Impact factor: 12.701

10.  TSH-lowering effect of metformin in type 2 diabetic patients: differences between euthyroid, untreated hypothyroid, and euthyroid on L-T4 therapy patients.

Authors:  Carlo Cappelli; Mario Rotondi; Ilenia Pirola; Barbara Agosti; Elena Gandossi; Umberto Valentini; Elvira De Martino; Antonio Cimino; Luca Chiovato; Enrico Agabiti-Rosei; Maurizio Castellano
Journal:  Diabetes Care       Date:  2009-06-05       Impact factor: 19.112

View more
  1 in total

1.  Assessment of serum prolactin levels in acute myocardial infarction: The role of pharmacotherapy.

Authors:  Hayder M Al-Kuraishy; Ali I Al-Gareeb; Mohamed S Awad; Sinan B Alrifai
Journal:  Indian J Endocrinol Metab       Date:  2016 Jan-Feb
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.